Epicrispr, Vaderis secure pivotal study funding for rare disease assets
The two companies have secured $90m and $152m, respectively, to take their drugs to pivotal development.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory
Turning AI skeptics into AI advocates through high-integrity data
Keeping pace with generative AI in pharmaceutical and healthcare organisations
Pharma Meets AI Conference 2026: Key barriers to scaling AI in drug development